Home » Stocks » PDL BioPharma

PDL BioPharma, Inc. (PDLI)

Stock Price: $2.26 USD 0.07 (3.20%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.29 +0.03 (1.33%) Oct 23, 4:21 PM

Stock Price Chart

Key Info

Market Cap 257.60M
Revenue (ttm) 49.58M
Net Income (ttm) -154.37M
Shares Out 113.98M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE 64.94
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.26
Previous Close $2.19
Change ($) 0.07
Change (%) 3.20%
Day's Open 2.20
Day's Range 2.19 - 2.27
Day's Volume 972,776
52-Week Range 1.89 - 3.50

More Stats

Market Cap 257.60M
Enterprise Value 113.06M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date Sep 21, 2020
Shares Outstanding 113.98M
Float 109.32M
EPS (basic) -1.31
EPS (diluted) -1.32
FCF / Share -0.09
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.85M
Short Ratio 10.77
Short % of Float 9.01%
Beta 0.89
PE Ratio n/a
Forward PE 64.94
P/FCF Ratio n/a
PS Ratio 5.20
PB Ratio 0.59
Revenue 49.58M
Operating Income -106.01M
Net Income -154.37M
Free Cash Flow -10.64M
Net Cash 144.54M
Net Cash / Share 1.27
Gross Margin 48.38%
Operating Margin -213.83%
Profit Margin -311.40%
FCF Margin -21.46%
ROA -4.10%
ROE -7.36%
ROIC -33.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$2.78*
Low
2.78
Current: $2.26
High
2.78
Target: 2.78
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue54.76198320244590581456381362345
Revenue Growth-72.36%-38.1%31.01%-58.62%1.59%27.39%19.79%5.2%4.95%-
Gross Profit1.14150290240590581456381362345
Operating Income-99.81-50.59194129550546427355344211
Net Income-70.41-68.8611163.6133332226521219991.87
Shares Outstanding119146155164163158140140140127
Earnings Per Share-0.59-0.470.710.392.031.861.661.451.150.54
EPS Growth--82.05%-80.79%9.14%12.05%14.48%26.09%112.96%-
Dividend Per Share---0.100.600.600.600.600.601.00
Dividend Growth----83.33%0%0%0%0%-40%-
Operating Cash Flow-32.44-13.4340.62102301292270213170184
Capital Expenditures76.8153.4510613.06-71.6021.31-241-0.05--
Free Cash Flow44.3740.0214711523031428.43212170184
Cash & Equivalents222458586353279351101176211246
Total Debt27.25125243232254452395310410515
Net Cash / Debt19433334212124.92-100-295-134-199-268
Assets7179641,2431,2151,012962544280269317
Liabilities124234397460316502430348474641
Book Value593730846751696460113-68.12-204-324
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PDL BioPharma, Inc.
Country United States
Employees 109
CEO Dominique P. Monnet

Stock Information

Ticker Symbol PDLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PDLI
IPO Date January 28, 1992

Description

PDL BioPharma manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.